Three patient deaths in Novartis' autoimmune CAR-T trials raise questions about risks of the therapy in non-fatal diseases.
FDA's Asha Das overruled agency reviewers to grant Replimune's melanoma drug Tudriqev accelerated approval, newly released memos show.
UK regulator halts Tavneos sales; uniQure seeks Huntington's gene therapy approval. Plus Regeneron, Novocure, Jazz, Ascendis, ...
Two pediatric deaths in Chinese CRISPR trials reignite debate over AAV delivery risks, as many of the 15 genetic-medicine ...
Google's Gemini now lets users book appointments via Zocdoc. Google Health Chief Michael Howell and Zocdoc CEO Oliver Kharraz ...
Trump strikes MFN drug-pricing deals with 9 more drugmakers as Incyte joins quietly; Oz says 600K seniors signed up for CMS ...
Lilly's 13 acquisitions in 2026, worth about $32B, are recycling cash back to at least 50 biotech venture investors.
Roche licenses Simcere Zaiming's preclinical trispecific T cell engager SIM0660 for $75M upfront, up to $1.53B in biobucks, its second China biotech deal this month.
Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward ...
ARCH Venture Partners is targeting $3B for its 14th fund, per an SEC filing, matching the size of the fund it disclosed in ...
Nine more drugmakers strike voluntary drug-pricing deals with the White House, pledging nearly $20B in US investments to avoid tariffs and CMS pricing pilots.
Sanofi-backed Electra files for a Nasdaq IPO to fund Phase 2/3 trials of ipsoprubart, its lead antibody for the rare disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results